Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 355-361

  Goss, P E ^a   Ingle, J N ^b   Martino, S ^c   Robert, N J ^d   Muss, H B ^e   Livingston, R B ^f   Davidson, N E ^g   Perez, E A ^h   Chavarri Guerra, Y ^a   Cameron, D A ⁱ   Pritchard, K I ^j   Whelan, T ^k   Shepherd, L E ^l   Tu, D ^l  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c Angeles Clinic and Research Institute   (United States)

^d INOVA FAIRFAX HOSPITAL   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h MAYO CLINIC CANCER CENTER   (United States)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^k MCMASTER UNIVERSITY   (Canada)

^l Queen's Cancer Research Institute   (Canada)

more..

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast cancer; Extended therapy; Letrozole; Menopausal status

Indexed keywords

LETROZOLE; PLACEBO;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; EDEMA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MENOPAUSE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; SURVIVAL RATE; SWEATING; VAGINA BLEEDING; VAGINAL DRYNESS;

EID: 84873868973     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds330     Document Type: Article

References (22)

1. Goss P, von Eichel L. Summary of aromatase inhibitor trials: the past and future. J Steroid Biochem Mol Biol 2007; 106: 40-48.
2. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-518.
3. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529-1542.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
5. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-690.
6. Stewart HJ, Forrest AP, Everington D et al. Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74: 297-299.
7. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zolendronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
8. Goss PE, Ingle JN, Martino S et al. A randomized trial of LET in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
9. Goss PE, Ingle JN, Martino S et al. Randomized trial of LET following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
10. Jin H, Tu D, Zhao N et al. Longer-term outcomes of letrozole versus placebo after 5 longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2011; 30: 718-721.
11. Goss PE, Ingle JN, Pater JL et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008; 26: 1948-1955.
12. Ingle JN, Tu D, Pater JL et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008; 19: 877-882.
13. Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast 2009; 18(Suppl 3): S122-S130.
14. Whelan TJ, Goss PE, Ingle JN et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23: 6931-6940.
15. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
16. Carlson RW, Allred DC, Anderson BO et al. NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7: 122-192.
17. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-3796.
18. ClinicalTrials.gov NCT00917969. http://clinicaltrials.gov/ct2/show/ NCT00917969?term=NCT00917969&rank=1 (19 January 2012, date last accessed).
19. ClinicalTrials.gov NCT00066703. http://clinicaltrials.gov/ct2/show/ NCT00066703?term=NCT0066703&rank=1 (19 January 2012, date last accessed).
20. Swain SM, Jeong JH, Geyer CE, Jr et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065.
21. Goss PE, Ingle JN, Martino S et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007; 25: 2006-2011.
22. Polyzos NP, Tzioras S, Badawy AM et al. Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod Biomed Online 2009; 19: 456-471.